Pedro Lichtinger, CEO and chairman of biotech Starton Therapeutics, speaks to EPM about the company’s mission to improve cancer care using transdermal technology.
At some point during a cancer patient’s treatment pathway there can come a trade-off between the desired level of drug they’re taking and just how well they tolerate the side-effects that inevitably come with treatment.
For people with cancer, the choice between extending their lives on a drug that will cause extremely unpleasant side-effects, versus forgoing treatment for a better remaining quality of life, is obviously a tough one.